Publications by authors named "Stephane Champiat"

Claim this Profile
A
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
Bingnan Zhang, Laura Alder, Samuel Rosner, Aakash Desai, Alissa J Cooper, Stephane Champiat

Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Proton Pump Inhibitors: Evaluating Treatment Strategies for Immune-Mediated Gastroenteritis from Cancer Immunotherapy.
Carolina Colli Cruz, Maria Julia Moura Nascimento Santos, Sharada Wali, Cristina Natha, Rachel Mortan, Stephane Champiat

Target Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit.
Camila Braganca Xavier, Clark R Andersen, JoAnn Lim, Julian H Slade, Stacie A Bean, Stephane Champiat

Cancer Res Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options.
Malek Shatila, Carolina Colli Cruz, Kei Takigawa, Andres Caleb Urias Rivera, Kian Abdul-Baki, Stephane Champiat

J Natl Compr Canc Netw· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.
Romain Guitton, Ariane Laparra, Noemie Chanson, Stephane Champiat, Francois-Xavier Danlos

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.
Kevin J Harrington, Stephane Champiat, Joshua D Brody, Byoung Chul Cho, Emanuela Romano

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint blockade efficacy.
Roman Vion, Matthieu Roulleaux-Dugage, Ronan Flippot, Kaïssa Ouali, Mathieu Rouanne, Stéphane Champiat

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors.
Oliver Bechter, Carmen Loquai, Stephane Champiat, Jean-Francois Baurain, Jean-Jacques Grob

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical Trials.
Ana Vaz Ferreira, Matthieu Delaye, Arnaud Pages, Antoine Hollebecque, Anas Gazzah, Stéphane Champiat

Drugs Aging· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial Intelligence for Drug Discovery: An Update and Future Prospects.
Harrison J Howell, Jeremy P McGale, Aurélie Choucair, Dorsa Shirini, Nicolas Aide, Stéphane Champiat

Semin Nucl Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp.
Volkan Beylergil, Laura Collins, Lawrence H Schwartz, Thomas Eche, Binsheng Zhao, Stephane Champiat

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
Jacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, Kelly G Paulson, Hossein Borghaei

Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers.
Stephane Champiat, Elena Garralda, Vladimir Galvao, Philippe A Cassier, Carlos Gomez-Roca

Cell Rep Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors.
Jason J Luke, David J Pinato, Dejan Juric, Patricia LoRusso, Peter J Hosein, Stéphane Champiat

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?
Antoine Mavrikios, Capucine Baldini, Yohann Loriot, Clémence Hénon, Aurélien Marabelle, Stéphane Champiat

Int J Radiat Oncol Biol Phys· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review.
Laurent Mathiot, Capucine Baldini, Octave Letissier, Antoine Hollebecque, Rastislav Bahleda, Stéphane Champiat

Curr Oncol Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
Afshin Dowlati, Horst-Dieter Hummel, Stephane Champiat, Maria Eugenia Olmedo, Michael Boyer

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.
Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R Lindsay, Iwona Lugowska, Stephane Champiat

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Arthur Géraud, Thomas Hueso, Ariane Laparra, Naike Bige, Kaissa Ouali, Stéphane Champiat

Eur J Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.
Layal Rached, Ariane Laparra, Madona Sakkal, François-Xavier Danlos, Fabrice Barlesi, Stéphane Champiat

Cancer Treat Rev· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.
Laurent Mathiot, David Combarel, Justin Cagnat, Julia Delahousse, Kaissa Ouali, Stephane Champiat

J Immunother Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial.
Julieta Rodriguez, Capucine Baldini, Arnaud Bayle, Arnaud Pages, François Xavier Danlos, Stephane Champiat

JCO Precis Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular surface toxicities associated with modern anticancer therapies.
Rafael Boucher, Oscar Haigh, Emmanuel Barreau, Stéphane Champiat, Olivier Lambotte

Surv Ophthalmol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody drug conjugates in older patients: State of the art.
Layal Rached, Arthur Geraud, Maxime Frelaut, Zoe Ap Thomas, Vincent Goldschmidt, Stephane Champiat

Crit Rev Oncol Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.
Emily Alouani, Ariane Laparra, Audrey Perret, Madonna Sakkal, Sabine Messayke, Stéphane Champiat

Eur J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis